Posts tagged as:

XPH

This year has shaped up to be quite kind to investors as major equity indexes are holding onto double-digit gains ahead of the anticipated Santa Claus rally. Much to the bears’ frustration, the U.S. economy has continued its slow and steady expansion while the Federal Reserve’s commitment to an accommodative monetary policy continues to resonate well on Wall Street [see The Complete History Of The S&P 500 Index].

Amid this bull run, investors have continued to embrace the exchange-traded product structure as the preferred means for accessing virtually any asset class out there. With over 1,500 ETFs on the market, active traders and buy-and-hold investors are able to tap into an array of strategies, some of which have delivered truly impressive gains thus far in 2013.

In the spirit of giving thanks today, below we take a look at seven ETF types that have racked up stellar returns year-to-date (as of 11/26/2013) for shareholders; for comparison, the broad U.S. market, as represented by the SPDR S&P 500 (SPY, A), has returned just over 28% YTD:

[click to continue…]

{ Comments on this entry are closed }

The U.S.’s growing aging population has made pharmaceutical spending a significant portion of our nation’s GDP, and has also affected job creation and stock market appreciation. This spike in national interest in healthcare has also occurred on Wall Street, where investors are embracing this market and its attractive growth potential. While there are some potential roadblocks and government decisions that could curb the industry’s growth, there are a few standout funds in the pharmaceutical sector battling for investor attention: PowerShares Dynamic Pharmaceuticals Portfolio (PJP, B+), iShares Dow Jones US Pharmaceuticals Index Fund  (IHE, B+) and SPDR S&P Pharmaceuticals  (XPH, B+) [Download How To Pick The Right ETF Every Time].

[click to continue…]

{ Comments on this entry are closed }

While some American’s were elated with Obama’s re-election, Wall Street made it quite clear who it had voted for as markets took a sharp nosedive in a post-election sell off immediately following the President’s victory. To many investors, Obama’s re-election has placed looming concerns over the Fiscal Cliff to the forefront, as the automatic round of […]

{ Comments on this entry are closed }

A sluggish manufacturing report had some investors heading for the hills today, as the latest bit of poor data signaled that the economic recovery is losing its quintessential momentum. According to the Institute of Supply Management’s purchasing managers’ index, activity in the manufacturing sector fell in August to its lowest level since July of 2009. […]

{ Comments on this entry are closed }

The year-end periods provides the ETF industry with a couple of opportunities to flex its collective muscle; performance comparisons generally tend to favor those products with lower expense ratios–a defining feature of exchange-traded funds. But early January also puts another benefit of exchange-traded products into focus: enhanced tax efficiency relative to traditional mutual funds. The […]

{ Comments on this entry are closed }

This time last year, investors were generally thrilled with the performances of their portfolios, which had continued to bounce back nicely from the devastating recession that hit in 2008. Unfortunately, few are feeling the same sense of accomplishment as 2011 draws to a close; this year has been frustrating in that a few large, swift […]

{ Comments on this entry are closed }

RBS rolled out its fifth ETN this week, debuting a product that offers exposure to the world’s largest pharmaceutical firms. The new Global Big Pharma ETN (DRGS) will seek to replicate the NYSE Arca Equal Weighted Pharmaceutical Total Return Index, a benchmark that consists of equal allocations to about 16 different companies involved in various […]

{ Comments on this entry are closed }

Pharmaceutical companies have long been popular investments as they offer relatively inelastic products as well as strong dividend yields that give both growth and value investors something to buy into. As far as the ETF world is concerned, there are four products that allow investors to gain access to this investment class. But with the […]

{ Comments on this entry are closed }

The U.S. House of Representatives worked late into the night on Sunday to pass historic health care legislation, capping months of intense debate and dealmaking. Sweeping changes to the nation’s health care system seemed like a done deal earlier this year before a major upset in a special Senate election sent Democrats back to the […]

{ Comments on this entry are closed }